Title: Increased expression of dopamine receptors on lymphocytes in Parkinson's disease
Abstract: Movement DisordersVolume 14, Issue 5 p. 764-771 Article Increased expression of dopamine receptors on lymphocytes in Parkinson's disease Piero Barbanti MD, PhD, Corresponding Author Piero Barbanti MD, PhD Department of Neurosciences, University "La Sapienza," RomeDepartment of Neurosciences, University "La Sapienza," Viale dell'Università, 30-00185-Rome, ItalySearch for more papers by this authorGiovanni Fabbrini MD, Giovanni Fabbrini MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorAlberto Ricci MD, Alberto Ricci MD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorRosanna Cerbo MD, Rosanna Cerbo MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorElena Bronzetti PhD, Elena Bronzetti PhD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorBrunella Caronti PhD, Brunella Caronti PhD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorCaterina Calderaro PhD, Caterina Calderaro PhD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorLaura Felici PhD, Laura Felici PhD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorFabrizio Stocchi MD, PhD, Fabrizio Stocchi MD, PhD I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, ItalySearch for more papers by this authorGiuseppe Meco MD, Giuseppe Meco MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorFrancesco Amenta MD, Francesco Amenta MD Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, ItalySearch for more papers by this authorGian Luigi Lenzi MD, Gian Luigi Lenzi MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this author Piero Barbanti MD, PhD, Corresponding Author Piero Barbanti MD, PhD Department of Neurosciences, University "La Sapienza," RomeDepartment of Neurosciences, University "La Sapienza," Viale dell'Università, 30-00185-Rome, ItalySearch for more papers by this authorGiovanni Fabbrini MD, Giovanni Fabbrini MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorAlberto Ricci MD, Alberto Ricci MD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorRosanna Cerbo MD, Rosanna Cerbo MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorElena Bronzetti PhD, Elena Bronzetti PhD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorBrunella Caronti PhD, Brunella Caronti PhD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorCaterina Calderaro PhD, Caterina Calderaro PhD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorLaura Felici PhD, Laura Felici PhD Department of Cardiovascular and Respiratory Sciences, University "La Sapienza," RomeSearch for more papers by this authorFabrizio Stocchi MD, PhD, Fabrizio Stocchi MD, PhD I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, ItalySearch for more papers by this authorGiuseppe Meco MD, Giuseppe Meco MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this authorFrancesco Amenta MD, Francesco Amenta MD Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, ItalySearch for more papers by this authorGian Luigi Lenzi MD, Gian Luigi Lenzi MD Department of Neurosciences, University "La Sapienza," RomeSearch for more papers by this author First published: 16 January 2001 https://doi.org/10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-WCitations: 63AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple-system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH-DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1-like (p <0.001) and D2-like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH-DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty-five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1-like (p <0.001) and D2-like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1-like and D2-like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD. REFERENCES 1Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985; 69: 223–230. 2Leenders KL, Antonini A, Schwartz J, Oertel WH, Hess K, Weindl A. Striatal dopamine D2-receptors in 'de novo' parkinsonian patients measured using PET and [11C]raclopride [Abstract]. Neurology 11992; 42: 295–296. 3Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44: 1325–1329. 4Churchyard A, Donnan A, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993; 34: 219–226. 5Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of post-synaptic mechanisms. Ann Neurol 1994; 36: 27–31. 6Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism. A prospective study. Can J Neurol Sci 1991; 18: 275–278. 7Rabey JM, Grynberg E, Graff E. Changes of muscarinic cholinergic binding by lymphocytes in Parkinson's disease with and without dementia. Ann Neurol 1991; 30: 847–850. 8Musanti R, Parati E, Lamperti E, Ghiselli G. Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson's disease. Biochem Med Metab Biol 1993; 49: 133–142. 9Factor SA, Ortof E, Dentinger MP, Dentinger MP, Mankes R, Barron KD. Platelet morphology in Parkinson's disease: an electron microscopic study. J Neurol Sci 1994; 122: 84–89. 10Bishopric NH, Cohen HJ, Lefkowitz RJ. Beta-adrenergic receptors in lymphocyte subpopulations. J Allergy Clin Immunol 1980; 63: 29–33. 11Meurs H, Van Den Bogaard W, Kauffmann HF, Bruynzeel PLB. Characterization of (-)-[3H]dihydroalprenolol binding to intact and broken cell preparations of human peripheral blood lymphocytes. Eur J Pharmacol 1982; 85: 185–194. 12Wiik P, Opstad PK, Boyum A. Binding of vasoactive intestinal polypeptide (VIP) by human monocytes: demonstration of specific binding sites. Regul Pept 1985; 12: 145–153. 13Evans CJ, Erdelyi E, Barchas JD. Candidate opioid peptides for the interaction with the immune system. In: NP Plotnikoff, RE Faith, AJ Murgo, A Goog, eds. Enkephalins and Endorphins. New York, NY: Plenum Press, 1986: 3–16. 14Stanisz AN, Scicchitano R, Dazin P, Bienenstock J, Payan DG. Distribution of substance P receptors on murine spleen and Peyer's patch T and B cells. J Immunol 1987; 139: 749–756. 15Shenkman L, Rabey JM, Gilad GM. Cholinergic muscarinic binding by rat lymphocytes: effects of antagonist treatment, strain and aging. Brain Res 1991; 564: 203–219. 16LeFur G, Phan T, Uzan A. Identification of stereospecific [3H]spiroperidol binding sites in mammalian lymphocytes. Life Sci 1980; 26: 1139–1148. 17LeFur G, Meininger V, Phan T, Gerard A, Baulac M, Uzan A. Decrease in lymphocyte [3H]spiroperidol binding sites in parkinsonism. Life Sci 1980; 27: 1587–1591. 18Maloteaux MJ, Goussin A, Waterkein C, Laduron PM. Trapping of labelled ligands in intact cells: a pitfall in binding studies. Biochem Pharmacol 1983; 32: 2543–2548. 19Czlonkowska A, Jachowicz-Jeszka J, Czlonkowski A. [3H]Spiperone binding to lymphocyte in extrapyramidal disease and aging. Brain Behav Immun 1987; 1: 197–203. 20Arnold G, Bondy B, Bandmann O, et al. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes. J Neural Transm 1993; 5: 107–116. 21Vile JM, Strange PG. High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. Biochem Pharmacol 1995; 49: 747–753. 22Takahashi N, Nagai Y, Ueno S, Saeki Y, Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett 1992; 314;1: 23–25. 23Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 1993; 194: 374–386. 24Bondy B, De Jong S, Pander S, Primbs J, Ackenheil M. Identification of dopamine D4 mRNA in circulating lymphocytes using nested polymerase chain reaction. J Neuroimmunol 1996; 71: 139–144. 25Ricci A, Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 1994; 53: 1–7. 26Ricci A, Veglio F, Amenta F. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7OH-DPAT. J Neuroimmunol 1995; 58: 139–144. 27Ricci A, Bronzetti E, Felici L, Tayebati SK, Amenta F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 1997; 229: 130–134. 28Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–752. 29McPherson GA. RADLIG Version 4. Cambridge: Biosoft, 1994. 30Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13: 61–69. 31Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16: 299–321. 32Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 264–270. 33Vile JM, Strange PG. High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. A long-tanding controversy. Biochem Pharmacol 1995; 49: 747–753. 34Vile JM, Strange PG. D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Biol Psychiatry 1996; 40: 881–885. 35Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptic. Nature 1990; 347: 146–151. 36Bondy B, Dengler FX, Oertel WH, Ackenheil M. 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in Parkinson patients. In: H Przuntek, P Riederer, eds. Early Diagnosis and Preventive Therapy in Parkinson's Disease. New York, NY: Springer-Verlag, 1989: 205–212. 37Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1995; 46: 791–795. 38Llau ME, Durrieu G, Tran MA, Senard JM, Rascol O, Montastruc JL. A study of dopaminergic sensitivity in Parkinson's disease: comparison in 'de novo' and levodopa-treated patients. Clin Neuropharmacol 1996; 19: 420–427. 39Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental denervation. Science 1985; 228: 1115–1117. 40Ferrero P, Rocca P, Eva C, et al. An analysis of lymphocyte 3H-N-methyl-scopolamine binding in neurological patients. Brain 1991; 114: 1759–1770. 41Zoukos Y, Thomaides T, Pavitt DV, Cuzner ML, Mathias CJ. B-adrenoreceptor expression on circulating mononuclear cells of idiopathic Parkinson's disease and autonomic failure patients before and after reduction of central sympathetic outflow by clonidine. Neurology 1993; 43: 1181–1187. Citing Literature Volume14, Issue5September 1999Pages 764-771 ReferencesRelatedInformation
Publication Year: 1999
Publication Date: 1999-09-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 88
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot